Vitrosorb
  • Home
    • About Vitrosorb
    • Product
    • Contact
    • News & Press
  • Okategoriserade 3
  • News 0
  • Slider 0
  • juni 2012

  • June 1, 2017 Vitrosorb are now in the final phase of getting the CE-marking for the SECORIM ABO columns A100, B100 and AB100.

    NEWS & PRESS

    June 1, 2017

    Vitrosorb are now in the final phase of getting the CE-marking for the SECORIM ABO columns A100, B100 and AB100.

  • Vitrosorb AB is a Swedish medical device company. Vitrosorb AB develop, produce and market immunadsorption columns aimed to eliminate the blood group barrier of organ transplantation. Vitrosorb’s main product SECORIM©-ABO, facilitates ABO-incompatible transplantations through reduction of blood group A or B antibodies. By eliminating the blood group barrier for organ transplantation, the number of transplantations is estimated to increase by 30 to 40 percent.

    VITROSORB AB

    Vitrosorb AB is a Swedish medical device company.

    Vitrosorb AB develop, produce and market immunadsorption columns aimed to eliminate the blood group barrier of organ transplantation. Vitrosorb’s main product SECORIM©-ABO, facilitates ABO-incompatible transplantations through reduction of blood group A or B antibodies. By eliminating the blood group barrier for organ transplantation, the number of transplantations is estimated to increase by 30 to 40 percent.

  • SECORIM©-ABO facilitates ABO-incompatible transplantations through reduction of blood group A or B antibodies. SECORIM©-ABO enables transplantations across blood group barriers by specific removal the organ recipient’s blood group antigens.

    SECORIM©-ABO

    SECORIM©-ABO facilitates ABO-incompatible transplantations through reduction of blood group A or B antibodies. SECORIM©-ABO enables transplantations across blood group barriers by specific removal the organ recipient’s blood group antigens.

© 2012 Vitrosorb AB. All Rights Reserved.